New minimally invasive treatments offer hope for patients with severe heart valve disease
Single bacteriophage used to treat immunocompromised patient with antibiotic resistant infection
11 May 2022Crisis-care protocols should ignore patients’ age, say ethicists
11 May 2022New minimally invasive treatments offer hope for patients with severe heart valve disease
National Heart Center Singapore (NHCS) now offers two new procedures—TricValve and TriClipTM—bringing a comprehensive suite of treatment options, ranging from medication therapies, minimally invasive (percutaneous or transcatheter) procedures, and surgical treatments to repair or replace the damaged valve, to patients with severe tricuspid valve problems. Being the early adopter for advanced valve therapies, NHCS was the first in Asia to introduce Transcatheter Aortic Valve Implantation (TAVI), also known as Percutaneous Aortic Valve Replacement (PAVR) in 2009, and also to perform minimally invasive heart valve repair using the MitraClip system in 2011.
